These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23928200)

  • 1. 1H magnetic resonance spectroscopy in multiple sclerosis and related disorders.
    Rovira A; Alonso J
    Neuroimaging Clin N Am; 2013 Aug; 23(3):459-74. PubMed ID: 23928200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Magnetic resonance spectroscopy and its clinical applications in multiple sclerosis].
    Watanabe H; Fukatsu H; Ito T; Iijima M; Mabuchi N; Sobue G
    Nihon Rinsho; 2003 Aug; 61(8):1435-41. PubMed ID: 12962035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MR spectroscopy in multiple sclerosis.
    De Stefano N; Filippi M
    J Neuroimaging; 2007 Apr; 17 Suppl 1():31S-35S. PubMed ID: 17425732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conventional and advanced magnetic resonance imaging in tumefactive demyelination.
    Saini J; Chatterjee S; Thomas B; Kesavadas C
    Acta Radiol; 2011 Dec; 52(10):1159-68. PubMed ID: 22025739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome.
    Stromillo ML; Giorgio A; Rossi F; Battaglini M; Hakiki B; Malentacchi G; Santangelo M; Gasperini C; Bartolozzi ML; Portaccio E; Amato MP; De Stefano N
    Neurology; 2013 Jun; 80(23):2090-4. PubMed ID: 23635962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic characterization of neurological diseases by proton localized NMR spectroscopy of the human brain.
    Confort-Gouny S; Vion-Dury J; Nicoli F; Dano P; Gastaut JL; Cozzone PJ
    C R Acad Sci III; 1992; 315(7):287-93. PubMed ID: 1336428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance spectroscopy findings as related to fatigue and cognitive performance in multiple sclerosis patients with mild disability.
    Pokryszko-Dragan A; Bladowska J; Zimny A; Slotwinski K; Zagrajek M; Gruszka E; Bilinska M; Sasiadek M; Podemski R
    J Neurol Sci; 2014 Apr; 339(1-2):35-40. PubMed ID: 24468541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis.
    Khan O; Shen Y; Bao F; Caon C; Tselis A; Latif Z; Zak I
    J Neuroimaging; 2008 Jul; 18(3):314-9. PubMed ID: 18304034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis.
    Arnold DL; Riess GT; Matthews PM; Francis GS; Collins DL; Wolfson C; Antel JP
    Ann Neurol; 1994 Jul; 36(1):76-82. PubMed ID: 8024266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies.
    De Stefano N; Filippi M; Miller D; Pouwels PJ; Rovira A; Gass A; Enzinger C; Matthews PM; Arnold DL
    Neurology; 2007 Nov; 69(20):1942-52. PubMed ID: 17998486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Differences in the spectroscopy of the lesions of the remitting relapsing form of multiple sclerosis shown by magnetic resonance].
    Martínez-Bisbal MC; Celda B; Martí-Bonmat L; Casanova-Estruch B; Coret-Ferrer F
    Rev Neurol; 2002 May 1-15; 34(9):807-12. PubMed ID: 12134339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton MRS: N-acetyl aspartate, creatine, and choline.
    Maton BM; Kuzniecky RI
    Adv Neurol; 2000; 83():253-9. PubMed ID: 10999207
    [No Abstract]   [Full Text] [Related]  

  • 13. Proton magnetic resonance spectroscopy in multiple sclerosis.
    Sajja BR; Wolinsky JS; Narayana PA
    Neuroimaging Clin N Am; 2009 Feb; 19(1):45-58. PubMed ID: 19064199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging.
    Husted CA; Goodin DS; Hugg JW; Maudsley AA; Tsuruda JS; de Bie SH; Fein G; Matson GB; Weiner MW
    Ann Neurol; 1994 Aug; 36(2):157-65. PubMed ID: 8053651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multiple sclerosis: imaging, diagnostic criteria and differential diagnosis].
    Harting I; Sellner J; Meyding-Lamadé U; Sartor K
    Rofo; 2003 May; 175(5):613-22. PubMed ID: 12743852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations of evoked potentials with MR imaging and MR spectroscopy in multiple sclerosis.
    Kraft GH; Richards TL; Heide AC
    Phys Med Rehabil Clin N Am; 1998 Aug; 9(3):561-7, vi. PubMed ID: 9894109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of magnetic resonance spectroscopy in the study of brain disease].
    Pérez-Gómez M; Junqué C; Mercader JM; Berenguer J
    Rev Neurol; 2000 Jan 16-31; 30(2):155-60. PubMed ID: 10730323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton MRS of large multiple sclerosis lesions reveals subtle changes in metabolite T(1) and area.
    Brief EE; Vavasour IM; Laule C; Li DK; Mackay AL
    NMR Biomed; 2010 Nov; 23(9):1033-7. PubMed ID: 20963799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis.
    De Stefano N; Bartolozzi ML; Guidi L; Stromillo ML; Federico A
    J Neurol Sci; 2005 Jun; 233(1-2):203-8. PubMed ID: 15949506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton magnetic resonance spectroscopy and diffusion-weighted imaging in intracranial cystic mass lesions.
    Lai PH; Hsu SS; Ding SW; Ko CW; Fu JH; Weng MJ; Yeh LR; Wu MT; Liang HL; Chen CK; Pan HB
    Surg Neurol; 2007; 68 Suppl 1():S25-36. PubMed ID: 17963918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.